Mobile

A randomized, open-label, multicenter study comparing the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan for DLL3high SCLC subjects with first relapse/recurrence followi...

Mise à jour : Il y a 4 ans
Référence : NCT03061812

A randomized, open-label, multicenter study comparing the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan for DLL3high SCLC subjects with first relapse/recurrence following front-line platinum-based chemotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to assess treatment with rovalpituzumab tesirine imrpoves objective response rate (ORR) and overall survival rate (OS) compared to topotecan in subjects with DLL3high SCLC who have first disease progression during or following front-line platinum based chemotherapy.

Critère d'inclusion

  • Small Cell Lung Cancer

Liens